Avantor(US:AVTR)2024-07-26 14:59Q2 2024 Financial Performance - Reported Revenue was $1.703 billion, a decrease of 2.0% compared to Q2 2023's $1.744 billion[12] - Organic growth decreased by 9.1%[12] - Adjusted Gross Profit was $583 million, representing 34.2% of revenues[12] - Adjusted EBITDA was $306 million, or 17.9% of revenues[12] - Adjusted Earnings Per Share (EPS) was $0.25[12] - Free Cash Flow was $235 million[12] Segment Performance - Laboratory Solutions reported revenue of $1.156 billion with organic growth of -2.7% and adjusted operating margin of 13.1%[16] - Bioscience Production reported revenue of $547 million with organic growth of -0.3% and adjusted operating margin of 26.3%[17] Full Year 2024 Guidance (Reaffirmed) - Organic Revenue Growth is projected to be between -2% and +1%[19] - Reported Revenue is expected to be between $6.85 billion and $7.06 billion, representing a reported growth of -1.7% to +1.3%[19] - Adjusted EBITDA Margin is projected to be between 17.4% and 17.9%, resulting in Adjusted EBITDA of $1.19 billion to $1.26 billion[19] - Adjusted EPS is expected to be between $0.96 and $1.04[19] - Free Cash Flow is projected to be between $600 million and $650 million, excluding approximately $100 million in cash costs related to the cost transformation initiative[19]